Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors.

Abstract

Monogenic periodic fever syndromes are heterogeneous group of autoinflammatory diseases including distinct syndromes, such as cryopyrin-associated periodic syndrome (CAPS), tumor necrosis factor alpha receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). Individual diseases differ in pathogenesis, clinical manifestations, and severity. However, cytokines from the interleukin 1 (IL-1) family play a key role in all of them. Inhibition of these cytokines, especially IL-1, thus plays a crucial role in their treatment. At present, we have a wide range of drugs that differ in structure, mechanism of action, efficacy, and spectrum of side effects. The most available are anakinra, canakinumab and rilonacept. Moreover, several clinical trials are currently underway with other very promising drugs, such as gevokizumab, tadekinig alfa or tranilast. In the following review, we provide a new perspective on the efficacy and safety of IL-1 inhibitors that have provided the novel results coming from recently published clinical trials.

• Authors: Tomáš Milota, Hana Malcová, Zuzana Střížová, Dita Cebecauerová, Rudolf Horváth
• Journal: Casopis lekaru ceskych (Cas Lek Cesk) Vol. 161 Issue 1 Pg. 3-10 ( 2022) ISSN: 0008-7335 [Print] Czech Republic
• Vernacular Title: Současné možnosti léčby monogenních syndromů periodických horeček - úloha inhibitorů interleukinu 1.
• PMID: 35354288 (Publication Type: Journal Article)

Chemical References

• Interleukin Inhibitors
• Interleukin-1

Topics

• Cryopyrin-Associated Periodic Syndromes (drug therapy)
• Hereditary Autoinflammatory Diseases (drug therapy)
• Humans
• Interleukin Inhibitors
• Interleukin-1 (therapeutic use)
• Mevalonate Kinase Deficiency (drug therapy)